Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...
Pancreatic Cancer Action Network5d
KRAS Mutations and Pancreatic Cancer
Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...
Frontiers6d
Targeting Cellular Signalling Pathways for Disease Therapy: The Potential of Cellular Reprogramming and Protein Kinase Inhibitors
Cellular reprogramming is an intrinsic evolutionary trait to constantly promote adaptations that confer survival advantage.
blog.lib.umn.edu1d
RAS (Reticular Activating System)
How can you use your subconscious mind to help you focus on the positive in your community? Learn how to ignite your RAS for good. Note: Two for You written transcripts are generated using a ...
C&EN6d
BRAFPred: A Novel Approach for Accurate Prediction of the B-Type Rapidly Accelerated Fibrosarcoma Inhibitor
School of Computer, Jiangsu University of Science and Technology, 666 Changhui Road, Zhenjiang 212100, China State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM) ...
Royal Aeronautical Society5d
Advancing the Future of Aerospace
Voting in the Royal Aeronautical Society Council elections is now open. Voting members can now vote to influence the way the Society is run and our future in aerospace. Cast your vote today! RAeS ...